Literature DB >> 8219665

Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists.

H Schwörer1, G Ramadori.   

Abstract

Generalized pruritus is a well-known, distressing symptom of various diseases, especially in hepatic cholestasis and chronic renal insufficiency. Its treatment is often unsatisfactory. In three patients with generalized pruritus, intravenous administration of the serotonin type 3 (5-HT3) receptor antagonist ondansetron induced a marked relief of itching. The effect was most pronounced in a patient with cholestasis-associated pruritus. It is suggested that serotonin, acting via 5-HT3 receptors, is involved in the generation and/or sensation of pruritus. Furthermore, 5-HT3 receptor antagonists may be a novel therapeutic principle for the treatment of pruritus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219665     DOI: 10.1007/bf00184497

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  9 in total

Review 1.  5-Hydroxytryptamine receptors.

Authors:  E Zifa; G Fillion
Journal:  Pharmacol Rev       Date:  1992-09       Impact factor: 25.468

Review 2.  Management of the pruritus of cholestasis: potential role of opiate antagonists.

Authors:  N V Bergasa; E A Jones
Journal:  Am J Gastroenterol       Date:  1991-10       Impact factor: 10.864

Review 3.  Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.

Authors:  A E Kidgell; M E Butcher; G W Brown
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

4.  Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs.

Authors:  B P Richardson; G Engel; P Donatsch; P A Stadler
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

Review 5.  Pruritus. Current concepts in pathogenesis and treatment.

Authors:  G Lorette; L Vaillant
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 6.  Ondansetron metabolism and pharmacokinetics.

Authors:  J F Pritchard
Journal:  Semin Oncol       Date:  1992-08       Impact factor: 4.929

Review 7.  Pharmacology and preclinical antiemetic properties of ondansetron.

Authors:  M B Tyers
Journal:  Semin Oncol       Date:  1992-08       Impact factor: 4.929

Review 8.  Pruritus in hepatic cholestasis. Pathogenesis and therapy.

Authors:  J M Garden; J D Ostrow; H H Roenigk
Journal:  Arch Dermatol       Date:  1985-11

9.  Subhypnotic doses of propofol relieve pruritus associated with liver disease.

Authors:  A Borgeat; O H Wilder-Smith; G Mentha
Journal:  Gastroenterology       Date:  1993-01       Impact factor: 22.682

  9 in total
  15 in total

Review 1.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

2.  Why do cholestatic patients itch?

Authors:  E A Jones; N V Bergasa
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

Review 3.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

4.  Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study.

Authors:  Mahmoud Gholyaf; Vida Sheikh; Fatemeh Yasrebifar; Younes Mohammadi; Mahtabalsadat Mirjalili; Maryam Mehrpooya
Journal:  Int Urol Nephrol       Date:  2020-05-07       Impact factor: 2.370

Review 5.  Pruritus: management algorithms and experimental therapies.

Authors:  Martin Steinhoff; Ferda Cevikbas; Akihiko Ikoma; Timothy G Berger
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 6.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

7.  Ondansetron for paediatric uraemic pruritus: a case report.

Authors:  Pankaj V Deshpande
Journal:  Pediatr Nephrol       Date:  2004-04-15       Impact factor: 3.714

Review 8.  5-HT3 receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 9.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 10.  Pruritus in chronic liver disease: mechanisms and treatment.

Authors:  Nora V Bergasa
Journal:  Curr Gastroenterol Rep       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.